Inhibition of TRAP-6-induced platelet aggregation with crizanlizumab vs inclacumab in healthy control human whole blood. Venous blood drawn from 12 healthy control human subjects and used in a whole blood platelet aggregation assay, as described in “Methods.” One-way analysis of variance vs vehicle control: ∗P ≤ .05; ∗∗P ≤ .01; ∗∗∗P ≤ .001; ∗∗∗∗P ≤ .0001. Error bars show the standard deviation (SD).